Rushang Patel, MD

Overview

Rushang Patel, MD completed fellowships in bone marrow transplant at Temple University and in hematology/oncology at Fox Chase Cancer Center, one of only 21 prestigious National Comprehensive Cancer Networks (NCCN) in the country. Board-certified in internal medicine and board eligible in medical oncology and hematology, Dr. Patel brings a wealth of clinical knowledge and in-depth research experience to both patient and practice, having worked on projects for United Nations International Children's Emergency Fund (UNICEF), Alembic Pharmaceuticals and Sanofi-Aventis, as well as having conducted studies focused on the mechanisms of cancer formation due to toxic chemicals and identifying new targets for designing cancer drugs

Articles

A Phase 2, Single-Arm, Multicohort, Open Label, Multicenter Trial of Off-the-Shelf Natural Killer Cells (SAR445419) in Patients with High-Risk Myeloid Malignancies Undergoing Allogeneic HSCT

BLOOD

2023

Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation

ANNALS OF HEMATOLOGY

2022

Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience

INTERNATIONAL JOURNAL OF HEMATOLOGY

2022

Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes

LEUKEMIA RESEARCH

2021

Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective

TRANSPLANTATION AND CELLULAR THERAPY

2021

Impact of Next-Generation Sequencing Cell-free Pathogen DNA Test on Antimicrobial Management in Adults with Hematological Malignancies and Transplant Recipients with Suspected Infections

TRANSPLANTATION AND CELLULAR THERAPY

2021

Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation

DIAGNOSTICS

2021

Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia

LEUKEMIA & LYMPHOMA

2020

Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

2019

Increased bone marrow CD56(bright) natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome

BONE MARROW TRANSPLANTATION

2019

Associated Clinical Trials

NCT05653271

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies

$Icon for trial | ACE1831-001 A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies$

This study is currently enrolling.

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies

NCT05107856

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection in Patients with Relapsed/Refractory Hematologic Malignancies

$Icon for trial | PRT1419-03 A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection in Patients with Relapsed/Refractory Hematologic Malignancies$

This study is currently enrolling.

The purpose of this research study is to test the safety of PRT1419 at different dose levels to find out what effects, good and/or bad, PRT1419 has on you and your type of cancer. The information collected from you and from oth ...

NCT04161885

A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)

This study is currently enrolling.

The purpose of this study is to evaluate the safety and efficacy of study drugs venetoclax and azacitidine compared to Best Supportive Care (no study medication) when given as maintenance therapy after allogeneic stem cell tran ...

NCT04637763

CB-010: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

$Icon for trial | CB-010 CB-010: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)$

This study is currently enrolling.

Allogeneic CAR-T cell therapy is a type of cancer therapy in which a healthy donor’s T cells (a type of immune system cell that circulates in blood) are modified during manufacturing using CRISPR genome editing so that those T ...

NCT04923893

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

A study comparing VRd followed by ciltacabtagene autoleucel, versus VRd followed by Rd Therapy in Subjects with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy ...

NCT03926624

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine Decitabine, Venetoclax combination regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage.

This study will investigate whether a new experimental treatment, DFP-10917, will be an effective and safe treatment option for patients with relapsed/refractory acute myelogenous leukemia (AML). The purpose of this study is to ...

Rushang Patel , MD

Overview

Articles

A Phase 2, Single-Arm, Multicohort, Open Label, Multicenter Trial of Off-the-Shelf Natural Killer Cells (SAR445419) in Patients with High-Risk Myeloid Malignancies Undergoing Allogeneic HSCT

Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation

Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience

Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes

Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective

Impact of Next-Generation Sequencing Cell-free Pathogen DNA Test on Antimicrobial Management in Adults with Hematological Malignancies and Transplant Recipients with Suspected Infections

Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation

Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia

Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation

Increased bone marrow CD56(bright) natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome

Education & Training

Education

Residency

Fellowship

Specialty

Board Certifications

Associated Clinical Trials

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection in Patients with Relapsed/Refractory Hematologic Malignancies

A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)

CB-010: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine Decitabine, Venetoclax combination regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage.

Explore

Institutes